Innovation in pharma: pioneering for patients
Galapagos is pioneering for patients at the level of both research and development, and in their business culture. We aim to help patients through discovery of breakthrough therapies for diseases with large unmet medical need.
Using human primary cells, we discover previously unknown drug targets, which play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease and fibrosis. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby address the course of the disease, rather than just treating the symptoms.
Our pipeline ranges from discovery to end-stage clinical programs in inflammation, fibrosis and other indications. Innovation at Galapagos goes with a culture of embracing change, no fear of failure and a ‘make it happen’ mentality.
Galapagos’ ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people’s lives.